10-Q: Kraig Biocraft Laboratories Reports Increased Net Loss in Q2 2024 Amidst Rising Operating Expenses

Kraig Biocraft Laboratories reported a net loss of $2.11 million for the six months ended June 30, 2024, as operating expenses significantly increased.

Summary

• Kraig Biocraft Laboratories reported a net loss of $2.11 million for the six months ended June 30, 2024, compared to a net loss of $1.16 million for the same period in 2023.
• The company's operating expenses increased to $1.93 million for the first six months of 2024, up from $0.97 million in the same period of 2023.
• General and administrative expenses saw a substantial increase, rising to $1.26 million from $0.43 million year-over-year.
• Professional fees also increased significantly to $0.18 million from $0.07 million year-over-year.
• Research and development expenses decreased to $0.08 million from $0.13 million year-over-year.
• The company's cash and cash equivalents decreased to $1.52 million as of June 30, 2024, from $2.55 million at the end of 2023.
• The company has a working capital deficit of $7.61 million and a stockholders deficit of $6.97 million as of June 30, 2024.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan.

Sentiment

Score: 3

Explanation: The document indicates a concerning financial situation with increasing losses, decreasing cash reserves, and a significant working capital deficit. The company's ability to continue as a going concern is in doubt, which is a major negative. While there are some positive aspects related to research and development, the overall sentiment is negative due to the financial challenges.

Positives

• The company's investment in gold bullion increased in value by $64,189 during the six months ended June 30, 2024.
• The company is continuing to work with its non-CRISPR Cas9 platform technology to accelerate its R&D operations.
• The company is refining its approach for targeted end-market applications.
• The company is simultaneously working with other technologies to advance, accelerate, and broaden its genetic engineering capabilities.

Negatives

• The company's net loss increased significantly year-over-year.
• Operating expenses have doubled, primarily due to increases in general and administrative costs and professional fees.
• The company's cash reserves have decreased substantially.
• The company has a significant working capital and stockholders deficit.
• The company's ability to continue as a going concern is in doubt.
• The company impaired a right-of-use asset by $30,084 due to lease termination negotiations.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company's current cash resources are insufficient to meet its planned business objectives without additional financing.
• There is no assurance that future financing will be available or on satisfactory terms.
• The company's operations are subject to risks inherent in growing an enterprise, including limited capital resources and risks in the research and development process.
• The company's business is subject to possible rejection of its products in development.
• The company's production operations in 2022 and early 2023 were hampered by unseasonable climate fluctuations and poor robustness of the silkworm strains.

Future Outlook

The company plans to expand research and development, develop a line of fabrics and apparel, expand spider silk production capacity, improve the robustness of recombinant spider silk lines, accelerate microbiology and selective breeding programs, and pursue collaborative research and commercialization opportunities. The company also plans to consider buying an established revenue producing company in a compatible business.

Management Comments

• Management believes that new platform technologies will allow the company to outpace and surpass the performance of Dragon Silk.
• Management believes that the company will be able to target metric tons of capacity of its recombinant spider silk fiber per annum from its operations once it overcomes the current challenges and reaches maximum utilization.
• Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

Industry Context

The company operates in the specialty fiber and technical textile industries, which are characterized by the use of high-performance materials in various applications. The company's focus on recombinant spider silk aims to provide a sustainable and high-performance alternative to traditional materials. The company is using genetic engineering technologies to develop fibers with greater strength, resiliency and flexibility for use in its target markets.

Comparison to Industry Standards

• The company's lack of revenue and significant net losses are not in line with established companies in the textile and specialty fiber industries.
• Companies like DuPont (Kevlar) and Honeywell (Spectra) have established revenue streams and profitability, which Kraig Biocraft has yet to achieve.
• The company's reliance on research and development and its focus on a novel technology (recombinant spider silk) make direct comparisons difficult.
• The company's financial performance is more akin to early-stage biotech companies that are still in the development phase rather than established textile manufacturers.
• The company's cash burn rate and working capital deficit are concerning when compared to industry benchmarks for companies with similar market capitalization.

Related Party Transactions

• The company has significant related party transactions, including loans, accrued expenses, and royalty agreements with its CEO.
• As of June 30, 2024, the company owed $6,884,832 to related parties in accrued salaries and accrued interest.
• The company recorded $40,314 as an in-kind contribution of interest related to a loan from its CEO during the six months ended June 30, 2024.

Stakeholder Impact

• Shareholders are at risk due to the company's significant losses and the uncertainty of its ability to continue as a going concern.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company faces financial difficulties.
• Customers and suppliers may be affected by potential delays or disruptions in the company's operations.
• Creditors face increased risk due to the company's financial instability.

Next Steps

• The company plans to expand its research and development to accelerate the creation of next-generation materials and improve the robustness of its recombinant spider silk lines.
• The company plans to develop a line of fabrics and apparel, to create a line of spider silk based fashion and performance wear.
• The company plans to continue the expansion of its spider silk production capacity including new facilities and expansion of existing facilities.
• The company plans to continue and accelerate its work to improve the overall robustness of its recombinant spider silk lines.
• The company plans to accelerate both its microbiology and selective breeding programs, as well as provide more resources for its material testing protocols.
• The company will consider buying an established revenue producing company in a compatible business.
• The company will also actively consider pursuing collaborative research opportunities with private laboratories.
• The company plans to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile and other industries.
• The company plans to actively pursue additional collaborative commercialization, marketing and manufacturing opportunities with companies in the textile and material sectors.
• The company plans to actively pursue the development of commercial scale production of its recombinant materials.

Key Dates

Keywords

spider silk, recombinant DNA, genetically engineered silkworms, technical textile, specialty fiber, biotechnology, financial results, operating expenses, net loss, capital raise